Table 3. Univariate analysis of PFS according to eNOS polymorphisms in the training and validation cohorts.
| Training cohort | Validation cohort | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No. of Patients | No. of Events | Median PFS (95% CI) | HR (95% CI) | P | No. of Patients | No. of Events | Median PFS (95% CI) | HR (95% CI) | P | |
| Overall | 38 | 3.9 (2.7-5.7) | - | - | 73 | 4.6 (2.6-5.7) | - | - | ||
| eNOS-786 | ||||||||||
| TT | 15 | 15 | 2.6 (1.1-2.8) | 4.43 (2.08-9.42) | 0.0001 | 37 | 35 | 2.0 (1.6-2.1) | 5.81 (3.43-9.82) | <0.0001 |
| CC+TC | 26 | 23 | 5.8 (3.8-8.7) | 1.00 | 50 | 38 | 6.9 (5.6-14.5) | 1.00 | ||
| eNOS VNTR | ||||||||||
| 4bb | 26 | 25 | 2.8 (2.3-4.6) | 2.08 (1.01-4.29) | 0.046 | 62 | 52 | 2.5 (2.1-4.8) | 1.97 (1.18-3.31) | 0.010 |
| 4ab+4aa | 13 | 11 | 8.5 (3.8-15.3) | 1.00 | 24 | 21 | 6.1 (4.7-23.9) | 1.00 | ||
| eNOS+894 | ||||||||||
| GG | 18 | 16 | 2.8 (2.3-3.8) | 2.00 (1.00-3.99) | 0.049 | 42 | 40 | 2.5 (2.0-3.7) | 2.17 (1.35-3.49) | 0.001 |
| GT+TT | 23 | 22 | 5.5 (3.7-8.5) | 1.00 | 45 | 33 | 6.9 (4.8-12.8) | 1.00 | ||
| eNOS Haplotypes * (786/VNTR) | ||||||||||
| HT1/HT1 | 14 | 14 | 2.6 (1.1-2.8) | 5.43 (2.46-11.98) | <0.0001 | 35 | 33 | 2.0 (1.6-2.1) | 5.16 (3.06-8.68) | <0.0001 |
| Other | 25 | 22 | 5.8 (3.8-8.7) | 1.00 | 51 | 40 | 6.7 (5.0-13.8) | 1.00 | ||
PFS, progression-free survival; OS, overall survival; HR, hazard ratio.
*
Haplotypes (HT) 1 shows the allele T at eNOS-786 and allele 4b at eNOS VNTR. “Other” indicates haplotypes other than the one indicated.